Cytokinetics Announces Additional Data from ACACIA-HCM Presented at the HFSA Annual Scientific Meeting 2026
Cytokinetics presented additional ACACIA-HCM analyses at the HFSA 2026 annual meeting, showing aficamten significantly improved a novel composite exercise-performance metric (BEAP-RS) versus placebo in non-obstructive HCM (p<0.001). A responder analysis found 53% of aficamten patients achieved a clinically meaningful response in three or more domains versus 13% on placebo, with results previously published in Circulation.
Key figures
- Drug Name
- aficamten (MYQORZO)
- Phase Of Trial
- Phase 3
- Indication
- non-obstructive hypertrophic cardiomyopathy (nHCM)
- Trial name
- ACACIA-HCM
- Snda timing
- Q4 2026
- Beap rs pvalue
- <0.001
- Lvef below50 placebo
- 0.8%
- Lvef below50 aficamten
- 10.5%
- Patients on 15 or 20mg
- 80.7%
- Heart failure sae placebo
- 1.2%
- Peak vo2 response placebo
- 37%
- Heart failure sae aficamten
- 4.7%
- Peak vo2 response aficamten
- 45%
- Clinical response 3plus domains placebo
- 13%
- Clinical response 3plus domains aficamten
- 53%
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.